Vericel Analyst and Investor Day
Vericel will host a virtual Analyst and Investor Day on Friday, October 16, 2020, from 9:00 a.m. - 11:00 a.m. EST which will focus on NexoBrid. In addition to a general corporate update, Vericel executives will facilitate discussions with burn surgeon thought leaders on current burn debridement practices and how NexoBrid, upon approval, could change the current treatment paradigm for debridement of severe thermal burns.
The content of Vericel Corporation’s October 16, 2020 Investor Day is intended solely for analysts, investors and potential investors of our Company’s publicly-traded securities. In addition to providing a general corporate update, the information, statements and publications that form a part of this presentation are meant to educate the investment community regarding the potential United States market opportunity for NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) if the product is approved by the U.S. Food and Drug Administration (FDA). FDA has accepted for filing the recently-submitted Biologics License Application (BLA) for NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. As such, NexoBrid is currently an investigational product in the United States and FDA has not been determined the product to be safe or effective for treatment in humans.